Nautilus Biotechnology (NAUT) Accounts Payables (2020 - 2026)

Nautilus Biotechnology (NAUT) has 7 years of Accounts Payables data on file, last reported at $1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 41.02% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at $1.2 million (up 41.02% YoY), and the FY2025 full-year result was $943000.0, down 4.46% from the prior year.
• Accounts Payables improved to $1.2 million in Q1 2026, from $943000.0 in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $1.9 million in Q1 2024 to a low of $823000.0 in Q3 2022.
• A 5-year average of $1.2 million and a median of $1.2 million in 2023 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables surged 1172.82% in 2022 and slumped 54.78% in 2025, its largest moves.
• Tracing NAUT's Accounts Payables over 5 years: stood at $1.3 million in 2022, then gained by 28.85% to $1.6 million in 2023, then tumbled by 39.78% to $987000.0 in 2024, then slipped by 4.46% to $943000.0 in 2025, then climbed by 25.77% to $1.2 million in 2026.
• Business Quant data shows NAUT's Accounts Payables at $1.2 million in Q1 2026, $943000.0 in Q4 2025, and $893000.0 in Q3 2025.